BioAegis Therapeutics Secures $3,732,412 New Round

  • Feed Type
  • Date
  • Company Name
    BioAegis Therapeutics
  • Mailing Address
    Undisclosed Boston, MA 02108
  • Company Description
    BioAegis Therapeutics’ products will restore depleted levels of plasma gelsolin, an integral and ubiquitous, natural human protein, whose important clinical role is now emerging.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

Trending on Xconomy